다발성 경화증 신규 치료제 보고서(2026년)(2분기판)

The emerging therapy landscape is rapidly evolving as pharmaceutical and biotechnology companies develop innovative treatments that not only reduce inflammatory disease activity but also promote remyelination, neuroprotection, and long-term preservation of neurological function.

Multiple sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system, characterized by inflammation, demyelination, and progressive neurodegeneration. While currently approved disease-modifying therapies have significantly improved relapse management, substantial unmet needs remain in treating progressive forms of MS, repairing myelin damage, and preventing irreversible disability. Emerging therapies analysis provides comprehensive insights into investigational products, clinical development progress, mechanisms of action, technology platforms, sponsor activities, regulatory developments, and future commercialization opportunities.

Market Drivers

Growing Demand for Next-Generation Therapies

Increasing demand for therapies capable of slowing disability progression, promoting remyelination, and improving neurological recovery continues to drive investment in emerging MS therapies. Developers are expanding research beyond conventional immune suppression toward disease-modifying strategies that address the underlying biology of progressive disease.

Advances in Neuroimmunology Research

Improved understanding of immune dysregulation, neurodegeneration, and myelin repair mechanisms has accelerated the identification of novel therapeutic targets. Scientific advances in B-cell biology, microglial activation, and neuroinflammation are supporting the development of more targeted treatment approaches.

Expansion of Precision Medicine

Precision medicine is becoming increasingly important in multiple sclerosis through the use of biomarkers, genomic profiling, advanced MRI imaging, and digital neurological assessments. These technologies enable improved patient stratification and support the development of personalized treatment strategies.

Increasing Regulatory Support

Regulatory agencies continue to encourage neurological innovation through scientific guidance, adaptive clinical development approaches, and support for therapies addressing significant unmet medical needs, helping accelerate development of promising investigational treatments.

Market Restraints

Complex Disease Biology

Multiple sclerosis exhibits considerable biological and clinical heterogeneity across relapsing-remitting, secondary progressive, and primary progressive disease forms, making therapeutic development and clinical evaluation increasingly complex.

High Research and Development Costs

Emerging therapies require extensive preclinical research, long-duration clinical trials, advanced biomarker validation, and comprehensive long-term safety monitoring, resulting in substantial development costs.

Clinical Development Challenges

Long follow-up periods, evolving clinical endpoints, complex patient recruitment, and increasing regulatory expectations continue to present challenges for developers seeking to demonstrate meaningful improvements in disability progression and neurological recovery.

Emerging Therapy and Technology Insights

The global multiple sclerosis emerging therapies market can be segmented by clinical development phase, mechanism of action, therapeutic modality, disease subtype, developer type, and geography.

By clinical development phase, the market includes preclinical assets, Phase I, Phase II, Phase III, and regulatory review programs. Early- and mid-stage development continues to expand as developers investigate novel approaches for both relapsing and progressive disease.

By mechanism of action, emerging therapies include Bruton tyrosine kinase (BTK) inhibitors, B-cell therapies, remyelination therapies, neuroprotective agents, stem cell therapies, gene therapies, immune tolerance therapies, and other novel immunomodulatory approaches. BTK inhibitors and regenerative therapies represent some of the fastest-growing areas of innovation within the MS pipeline.

By therapeutic modality, investigational products include small molecules, monoclonal antibodies, biologics, cell therapies, gene therapies, RNA therapeutics, and combination therapies. Small molecules continue to dominate overall pipeline activity, while regenerative medicine and advanced biologic platforms are expanding rapidly.

By disease subtype, therapeutic development targets relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS), and clinically isolated syndrome (CIS), with increasing emphasis on therapies capable of slowing progressive neurological decline.

Technological advances in artificial intelligence, advanced MRI imaging, digital biomarkers, wearable monitoring technologies, decentralized clinical trials, real-world evidence, and computational drug discovery are improving clinical development efficiency and accelerating therapeutic innovation.

Emerging Therapy Development Trends

The multiple sclerosis therapeutic landscape continues to evolve beyond conventional anti-inflammatory treatment toward therapies capable of modifying long-term disease progression.

Key development trends include:

• Expansion of Bruton tyrosine kinase (BTK) inhibitor programs.
• Increasing investment in remyelination and regenerative medicine.
• Growing emphasis on neuroprotective therapies.
• Development of biomarker-guided precision medicine.
• Integration of artificial intelligence into drug discovery and clinical development.
• Expansion of stem cell and gene therapy research.
• Greater focus on progressive multiple sclerosis where significant unmet needs remain.

Strategic collaborations among pharmaceutical companies, biotechnology firms, academic institutions, and research organizations continue to accelerate innovation while strengthening the global emerging therapy pipeline.

Regional Insights

North America remains the leading region for multiple sclerosis emerging therapy development due to advanced neurological research infrastructure, strong biotechnology investment, extensive clinical trial activity, and supportive regulatory pathways.

Europe continues to play a major role through collaborative neuroscience research networks, established MS treatment centers, and centralized regulatory review processes supporting innovative neurological therapies.

Asia-Pacific is expected to witness the fastest growth during the forecast period owing to expanding biotechnology capabilities, increasing healthcare investment, improving neurological care infrastructure, and growing participation in multinational clinical trials across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually strengthening neurological research through improved healthcare infrastructure, increasing diagnostic capabilities, and expanding participation in international clinical development programs.

Competitive Landscape

The multiple sclerosis emerging therapies market includes multinational pharmaceutical companies, biotechnology firms, academic research institutions, contract research organizations, and neuroscience-focused innovators.

Developers continue investing in differentiated immunotherapies, regenerative medicine, biomarker-driven development, artificial intelligence-enabled drug discovery, and precision medicine technologies. Strategic licensing agreements, research collaborations, mergers and acquisitions, and co-development partnerships remain key strategies for accelerating innovation and strengthening competitive positioning.

Future Outlook

The future of the multiple sclerosis emerging therapies market is expected to be driven by continued advances in neuroimmunology, regenerative medicine, biomarker science, artificial intelligence, and personalized neurology. Future innovation will increasingly focus on therapies capable of repairing myelin, preventing axonal degeneration, restoring neurological function, and slowing irreversible disability progression.

Precision medicine approaches integrating genomic profiling, advanced imaging biomarkers, and digital neurological monitoring are expected to improve patient selection, optimize treatment outcomes, and accelerate regulatory approvals.

Conclusion

The global Multiple Sclerosis Emerging Therapies Analysis market is expected to experience substantial growth through 2035, supported by expanding investment in neuroscience research, increasing development of next-generation disease-modifying therapies, advances in regenerative medicine, and growing adoption of precision medicine. Although challenges related to disease heterogeneity, lengthy clinical development, and regulatory complexity remain, continued innovation in BTK inhibitors, remyelination therapies, neuroprotective agents, biomarker-guided treatment, and artificial intelligence is expected to transform the future therapeutic landscape and create significant opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, and investors.

Key Benefits of this Report

• Comprehensive analysis of the global multiple sclerosis emerging therapies landscape and future innovation trends.
• Detailed evaluation of investigational therapies, novel mechanisms of action, and therapeutic technologies.
• Competitive assessment of leading developers, strategic collaborations, and pipeline advancements.
• Insights into regulatory developments, commercialization opportunities, and future therapeutic strategies.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Pipeline assessment, competitive intelligence, licensing and partnership evaluation, portfolio optimization, investment analysis, commercialization planning, clinical development strategy, regulatory planning, and identification of future market opportunities.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the multiple sclerosis emerging therapies landscape by clinical development phase, mechanism of action, therapeutic modality, disease subtype, developer type, and geography
• Evaluation of investigational therapies, clinical development progress, regulatory milestones, and innovation trends
• Assessment of pipeline assets, strategic collaborations, licensing agreements, mergers and acquisitions, and competitive positioning
• Analysis of precision medicine, regenerative medicine, biomarker integration, artificial intelligence, and future commercialization opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Pipeline Highlights
  • 1.2.1 Total Active Emerging Therapies
  • 1.2.2 Clinical Development Distribution
  • 1.2.3 Innovation Trends
  • 1.2.4 Regulatory Momentum
• 1.3 Key Strategic Findings
• 1.4 Executive Dashboard
  • 1.4.1 Assets by Clinical Phase
  • 1.4.2 Assets by Mechanism of Action
  • 1.4.3 Assets by Modality
  • 1.4.4 Assets by Developer Type
  • 1.4.5 Expected Regulatory Milestones

2. Pipeline Overview

• 2.1 Multiple Sclerosis Pipeline Landscape
• 2.2 Current Pipeline Size and Evolution
• 2.3 Historical Pipeline Growth Trends
• 2.4 Clinical Development Distribution
  • 2.4.1 Preclinical Assets
  • 2.4.2 Phase I Assets
  • 2.4.3 Phase II Assets
  • 2.4.4 Phase III Assets
  • 2.4.5 Filed / Under Regulatory Review Assets
• 2.5 Pipeline Attrition Trends
• 2.6 Pipeline Maturity Assessment
• 2.7 Innovation Index
• 2.8 Sponsor Landscape
  • 2.8.1 Large Pharmaceutical Companies
  • 2.8.2 Biotechnology Companies
  • 2.8.3 Academic Institutions
  • 2.8.4 Collaborative Development Programs

3. Disease and Unmet Need Analysis

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Disease Burden
• 3.4 Current Treatment Landscape
• 3.5 Remaining Clinical Challenges
  • 3.5.1 Progressive Disease Management
  • 3.5.2 Neuroprotection
  • 3.5.3 Remyelination
  • 3.5.4 Disability Progression
  • 3.5.5 Cognitive Impairment
• 3.6 Treatment Gaps Driving Pipeline Innovation
• 3.7 Future Therapeutic Priorities

4. Mechanism and Modality Landscape

• 4.1 Mechanism of Action Landscape
• 4.2 Mechanism-Based Clustering
  • 4.2.1 BTK Inhibitors
  • 4.2.2 Anti-CD20 Therapies
  • 4.2.3 Remyelination Therapies
  • 4.2.4 Neuroprotective Therapies
  • 4.2.5 Immune Reconstitution Approaches
  • 4.2.6 S1P Receptor Modulators
  • 4.2.7 Cytokine and Immune Modulators
  • 4.2.8 Other Emerging Mechanisms
• 4.3 Novel versus Established Mechanisms
• 4.4 First-in-Class versus Best-in-Class Assessment
• 4.5 Modality Landscape
  • 4.5.1 Small Molecules
  • 4.5.2 Monoclonal Antibodies
  • 4.5.3 Cell Therapies
  • 4.5.4 Gene Therapies
  • 4.5.5 RNA-Based Therapeutics
  • 4.5.6 Peptide-Based Therapies
  • 4.5.7 Other Advanced Modalities
• 4.6 Innovation Benchmarking
• 4.7 Mechanism Diversification Trends

5. Clinical Development Intelligence

• 5.1 Clinical Development Overview
• 5.2 Trial Design Benchmarking
  • 5.2.1 Sample Size Analysis
  • 5.2.2 Primary Endpoints
  • 5.2.3 Secondary Endpoints
  • 5.2.4 Biomarker Utilization
  • 5.2.5 Imaging Endpoints
  • 5.2.6 Trial Duration
  • 5.2.7 Comparator Selection
• 5.3 Clinical Trial Recruitment Trends
• 5.4 Enrollment Performance
• 5.5 Geographic Recruitment Distribution
• 5.6 Clinical Success Rates
• 5.7 Historical Failure Analysis
• 5.8 Trial Discontinuation Trends
• 5.9 Safety and Tolerability Trends
• 5.10 Regulatory Designations
  • 5.10.1 Fast Track
  • 5.10.2 Breakthrough Therapy
  • 5.10.3 Orphan Designation
  • 5.10.4 Priority Review and Other Expedited Programs

6. Pipeline Segmentation

• 6.1 Pipeline by Clinical Phase
  • 6.1.1 Preclinical Pipeline Analysis
    • 6.1.1.1 Number of Assets
    • 6.1.1.2 Key Developers
    • 6.1.1.3 Innovation Assessment
  • 6.1.2 Phase I Pipeline Analysis
    • 6.1.2.1 Number of Assets
    • 6.1.2.2 Key Developers
    • 6.1.2.3 Early Clinical Trends
  • 6.1.3 Phase II Pipeline Analysis
    • 6.1.3.1 Number of Assets
    • 6.1.3.2 Mid-Stage Competitive Landscape
    • 6.1.3.3 Clinical Readout Expectations
  • 6.1.4 Phase III Pipeline Analysis
    • 6.1.4.1 Number of Assets
    • 6.1.4.2 Registrational Development Programs
    • 6.1.4.3 Commercial Readiness
  • 6.1.5 Filed / Under Review Assets
    • 6.1.5.1 Regulatory Submission Status
    • 6.1.5.2 Expected Approval Timelines
• 6.2 Pipeline by Mechanism of Action
• 6.3 Pipeline by Therapeutic Modality
• 6.4 Pipeline by Route of Administration
• 6.5 Pipeline by Molecule Type
• 6.6 Pipeline by Target Patient Population
• 6.7 Pipeline by Sponsor Type

7. Asset-Level Pipeline Intelligence

• 7.1 Asset Profiling Methodology
• 7.2 Individual Asset Intelligence
  • 7.2.1 Molecule Profile
    • 7.2.1.1 Developer
    • 7.2.1.2 Mechanism of Action
    • 7.2.1.3 Molecular Type
    • 7.2.1.4 Clinical Phase
    • 7.2.1.5 Target Indication
    • 7.2.1.6 Clinical Trial Summary
    • 7.2.1.7 Key Efficacy Findings
    • 7.2.1.8 Safety Profile
    • 7.2.1.9 Regulatory Status
    • 7.2.1.10 Development Timeline
    • 7.2.1.11 Commercial Outlook
    • 7.2.1.12 SWOT Assessment

8. Probability of Success and Risk Analysis

• 8.1 Probability of Success Methodology
• 8.2 Historical Phase Transition Rates
• 8.3 Phase-Specific Probability Modeling
  • 8.3.1 Preclinical to Phase I
  • 8.3.2 Phase I to Phase II
  • 8.3.3 Phase II to Phase III
  • 8.3.4 Phase III to Approval
• 8.4 Risk-Adjusted Pipeline Valuation
• 8.5 Attrition Analysis
• 8.6 Scientific Risk Assessment
• 8.7 Clinical Risk Assessment
• 8.8 Regulatory Risk Assessment
• 8.9 Commercial Risk Assessment
• 8.10 Probability-Weighted Revenue Forecast

9. Launch Timeline and Commercial Potential

• 9.1 Expected Approval Timeline
• 9.2 Launch Sequencing
• 9.3 Competitive Launch Window
• 9.4 Peak Sales Forecast
• 9.5 Market Penetration Analysis
• 9.6 Pricing Considerations
• 9.7 Reimbursement Outlook
• 9.8 Market Access Challenges
• 9.9 Commercial Opportunity Assessment

10. Competitive Pipeline Landscape

• 10.1 Competitive Environment
• 10.2 Company-Wise Pipeline Strength
• 10.3 Pipeline Asset Concentration
• 10.4 Leader versus Challenger Assessment
• 10.5 Innovation Leadership Matrix
• 10.6 Clinical Development Positioning
• 10.7 Competitive Benchmarking
• 10.8 Emerging Competitive Threats

11. Geographic Analysis

• 11.1 North America
  • 11.1.1 Clinical Trial Activity
  • 11.1.2 Regulatory Environment
  • 11.1.3 Innovation Hubs
• 11.2 Europe
  • 11.2.1 Clinical Trial Activity
  • 11.2.2 Regulatory Environment
  • 11.2.3 Innovation Hubs
• 11.3 Asia-Pacific
  • 11.3.1 Clinical Trial Activity
  • 11.3.2 Regulatory Environment
  • 11.3.3 Innovation Hubs
• 11.4 Latin America
  • 11.4.1 Clinical Trial Activity
  • 11.4.2 Regulatory Environment
  • 11.4.3 Innovation Hubs
• 11.5 Middle East & Africa
  • 11.5.1 Clinical Trial Activity
  • 11.5.2 Regulatory Environment
  • 11.5.3 Innovation Hubs

12. Key Countries Analysis

• 12.1 United States
  • 12.1.1 Clinical Trial Activity
  • 12.1.2 Regulatory Timelines
  • 12.1.3 Major Sponsors
• 12.2 Canada
  • 12.2.1 Clinical Trial Activity
  • 12.2.2 Regulatory Timelines
  • 12.2.3 Major Sponsors
• 12.3 Germany
• 12.4 United Kingdom
• 12.5 France
• 12.6 Italy
• 12.7 Spain
• 12.8 China
• 12.9 Japan
• 12.10 India
• 12.11 South Korea
• 12.12 Australia
• 12.13 Brazil
• 12.14 Mexico
• 12.15 Saudi Arabia
• 12.16 South Africa

13. Deals and Investment Landscape

• 13.1 Licensing Agreements
• 13.2 Co-development Partnerships
• 13.3 Strategic Collaborations
• 13.4 Merger and Acquisition Activity
• 13.5 Venture Capital Investments
• 13.6 Private Equity Funding
• 13.7 Public Market Financing
• 13.8 Government and Non-Profit Funding
• 13.9 Investment Trends by Technology Platform
• 13.10 Partnership Case Studies

14. Future Outlook and Strategic Insights

• 14.1 Emerging Scientific Trends
• 14.2 Next-Generation Therapeutic Platforms
• 14.3 Future Mechanistic Directions
• 14.4 Expected Clinical Catalysts
• 14.5 Regulatory Outlook
• 14.6 Commercialization Outlook
• 14.7 White Space Opportunities
• 14.8 Strategic Recommendations for Developers
• 14.9 Long-Term Competitive Outlook

15. Methodology and Data Framework

• 15.1 Research Methodology
• 15.2 Data Collection Framework
• 15.3 Pipeline Inclusion Criteria
• 15.4 Clinical Phase Classification Methodology
• 15.5 Asset Verification Framework
  • 15.5.1 Company Pipeline Verification
  • 15.5.2 Clinical Trial Registry Verification
  • 15.5.3 Regulatory Filing Verification
• 15.6 Probability Modeling Methodology
• 15.7 Commercial Forecasting Methodology
• 15.8 Risk Adjustment Methodology
• 15.9 Data Validation and Quality Control
• 15.10 Assumptions and Limitations
• 15.11 Abbreviations and Glossary
• 15.12 References and Verified Data Sources
  • 15.12.1 Company Pipeline Disclosures
  • 15.12.2 Clinical Trial Registries
  • 15.12.3 Regulatory Agency Publications
  • 15.12.4 Peer-Reviewed Scientific Literature
  • 15.12.5 Investor Presentations and Annual Reports